Top pick: Anand Rathi suggests this pharma stock to buy this month
Premium- Sharing as its top pick for the month, the brokerage has buy rating on the pharma stock with a target price of ₹1,070
Cipla shares have been under pressure since quiet some time but at this juncture its trading near its crucial support. Previously, the stock turned from this level and a rally towards ₹1,080 was seen, highlighted domestic brokerage and research firm Anand Rathi in a note.
Sharing as its top pick for the month, the brokerage has buy rating on the pharma stock with a target price of ₹1,070 per share and stop loss of ₹860 with a time frame on one month.
“On 4 HRS chart there is bullish BAT pattern which is looking lucrative, Thus, we advise traders to go long in the stock with a stop loss of ₹860," Anand Rathi added.
Drug major Cipla on Tuesday said its consolidated profit after tax declined by 12% to ₹362 crore for the fourth quarter ended March 2022 as compared to ₹413 crore in the January-March quarter of 2020-21 fiscal.
The Mumbai-based company's revenue from operations, however, rose to ₹5,260 crore for the period under review as against ₹4,606 crore in the fourth quarter of FY21, led by growth in One-India (+21% YoY) and US business (+21% YoY). Furthermore, the US business reported the highest ever sales of $160 million which was led by the respiratory franchisee and peptide assets.
Shares of Cipla have risen just about 5% in a year's period, whereas the stock is up 0.8% in 2022 (YTD) so far as compared to more than 8% fall in benchmark Sensex since the beginning of the year.
MINT PREMIUM See All
The views and recommendations made above are those of individual analysts or broking companies, and not of Mint.